RxDoctor Payments Data

Anumeha Kohli, MD

Internal Medicine · Austin, TXNPI 1932436532

Payments from drug & device makers

$3,435in general payments, 2019–2025

Across 232 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$367
  • GSK$367
  • Amgen$292
  • Boehringer Ingelheim$252
  • AstraZeneca$228
  • plus $871 from 14 others

What the payments were for

  • Food & beverage$3,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,435 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$136,266
Medicare patients
358
Services billed
1,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron50$42,027
TrulicityDulaglutide11$21,406
JardianceEmpagliflozin18$19,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,118
FarxigaDapagliflozin Propanediol21$17,292
OzempicSemaglutide12$17,231
RybelsusSemaglutide15$14,727
MounjaroTirzepatide14$13,596
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$12,047
LinzessLinaclotide20$11,861
Levothyroxine Sodium331$3,848
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$3,229
Atorvastatin Calcium332$3,096
Pitavastatin Calcium11$2,319
SynthroidLevothyroxine Sodium35$2,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$131$42,02750 claims
Lilly USA, LLCTrulicity, Mounjaro$201$35,00225 claims
Novo NordiskOzempic, Rybelsus$1,059$31,95827 claims
Boehringer IngelheimJardiance$252$19,81418 claims
GSKTrelegy Ellipta$367$19,11821 claims
AstraZenecaFarxiga$228$17,29221 claims
AbbVieLinzess, Synthroid, Armour Thyroid$367$15,39667 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →